NEW YORK, Aug. 16, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Xerostomia Therapeutics - Pipeline Assessment and Market Forecasts to 2019http://www.reportlinker.com/p0946316/Xerostomia-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2019.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy
Xerostomia Therapeutics - Pipeline Assessment and Market Forecasts to 2019
SummaryGlobalData, the industry analysis specialist, has released its new report, "Xerostomia Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Xerostomia Therapeutics market. The report identifies the key trends shaping and driving the global Xerostomia Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Xerostomia Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.ScopeThe report provides information on the key drivers and challenges of the Xerostomia Therapeutics market. Its scope includes -- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Xerostomia Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Xerostomia Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Xerostomia Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Xerostomia Therapeutics market
Reasons to buyThe report will enhance your decision making capability. It will allow you to -- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Xerostomia Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Xerostomia Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Xerostomia Therapeutics market landscape? – Identify, understand and capitalize.
Table of Contents1 Table of Contents1 Table of Contents 3
1.1 List of Tables 4
1.2 List of Figures 5
2 Xerostomia Therapeutics - Introduction 6
2.1 Disease Overview 6
2.2 Etiology and Pathogenesis 6
2.2.1 Complications of Xerostomia 9
2.3 Signs and Symptoms 10
2.4 Epidemiology 10
2.5 Socio-economic Status and Quality of Life 11
2.6 Diagnosis 11
2.7 Treatment and Management Pattern 13
2.8 Treatment Algorithm 14
2.9 Referral Pathway 15
2.10 GlobalData Pipeline Report Guidance 16
3 Xerostomia Therapeutics - Market Characterization 17
3.1 Xerostomia Therapeutics Market Size (2006 - 2011) - Global 17
3.2 Xerostomia Therapeutics Market Forecast (2011 - 2019) - Global 18
3.3 Xerostomia Therapeutics Market Size (2006 - 2011) - The US 19
3.4 Xerostomia Therapeutics Market Forecast (2011 - 2019) - The US 20
3.5 Xerostomia Therapeutics Market Size (2006 - 2011) - The UK 21
3.6 Xerostomia Therapeutics Market Forecast (2011 - 2019) - The UK 22
3.7 Xerostomia Therapeutics Market Size (2006 - 2011) - France 23
3.8 Xerostomia Therapeutics Market Forecast (2011 - 2019) - France 24
3.9 Xerostomia Therapeutics Market Size (2006 - 2011) - Germany 25
3.10 Xerostomia Therapeutics Market Forecast (2011 - 2019) - Germany 26
3.11 Xerostomia Therapeutics Market Size (2006 - 2011) - Italy 27
3.12 Xerostomia Therapeutics Market Forecast (2011 - 2019) - Italy 28
3.13 Xerostomia Therapeutics Market Size (2006 - 2011) - Spain 29
3.14 Xerostomia Therapeutics Market Forecast (2011 - 2019) - Spain 30
3.15 Xerostomia Therapeutics Market Size (2006 - 2011) - Japan 31
3.16 Xerostomia Therapeutics Market Size (2011 - 2019) - Japan 32
3.17 Drivers and Barriers for the Xerostomia Therapeutics Market 33
3.17.1 Drivers for the Xerostomia Therapeutics Market 33
3.17.2 Barriers for the Xerostomia Therapeutics Market 33
3.18 Opportunity and Unmet Need Analysis 34
3.19 Key Takeaway 35
4 XerostomiaTherapeutics - Competitive Assessment 36
4.1 Overview 36
4.2 Strategic Competitor Assessment 36
4.3 Product Profiles for the Major Marketed Products in the Xerostomia Therapeutics Market 37
4.3.1 Evoxac (cevimeline) 37
4.3.2 Ethyol (amifostine) 38
4.3.3 Pilocarpine Hydrochloride 38
4.4 Key Takeaway 40
5 Xerostomia Therapeutics Market - Pipeline Assessment 41
5.1 Overview 41
5.2 Strategic Pipeline Assessment 41
5.3 Xerostomia Therapeutics Pipeline - Pipeline by Phases of Development 41
5.3.1 Xerostomia Therapeutics - Phase II Pipeline 41
5.3.2 Technology Trends Analytic Framework 42
5.4 Xerostomia Therapeutics Market - Pipeline by Mechanism of Action 43
5.5 Molecules Profiles for Pipeline Drugs Under Development 43
5.5.1 P-552-02 43
5.5.2 APD515 43
5.5.3 Pilobuc 44
5.6 Key Takeaway 44
6 Xerostomia Therapeutics - Clinical Trials Mapping 45
6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 45
6.2 Clinical Trials by Phase 46
6.3 Clinical Trials by Trial Status 47
6.4 Clinical Trials by Sponsors 48
6.5 Top Companies Participating in Xerostomia Therapeutics Clinical Trials 50
7 XerostomiaTherapeutics - Strategic Assessment 51
7.1 Key Events Impacting the Future Market 51
7.2 Xerostomia Therapeutics - Implications for Future Market Competition 51
8 Xerostomia Disease Therapeutics - Future Players 53
8.1 Introduction 53
8.2 Parion Sciences 53
8.2.1 Company Overview 53
8.2.2 Sjogren's Syndrome (Associated with Xerostomia) Therapeutics Pipeline 54
8.3 Acacia Pharma 54
8.3.1 Company Overview 54
8.3.2 Xerostomia Therapeutics Pipeline 54
8.4 Marillion Pharmaceuticals 55
8.4.1 Company Overview 55
8.4.2 Xerostomia Therapeutics Pipeline 55
9 Xerostomia Therapeutics - Licensing and Partnership Deals 56
10 XerostomiaTherapeutics - Appendix 57
10.1 Market Definitions 57
10.2 Abbreviations 57
10.3 Research Methodology 57
10.3.1 Coverage 58
10.3.2 Secondary Research 58
10.3.3 Forecasting 58
10.3.4 Primary Research 60
10.3.5 Expert Panel Validation 60
10.4 Contact Us 60
10.5 Disclaimer 60
10.6 Bibliography 61
List of Tables1.1 List of TablesTable 1: Extra-oral Signs Frequently Observed in Connection with Xerostomia and Salivary Gland Hypofunction 10
Table 2: Prevalence of Xerostomia 10
Table 3: Xerostomia Therapeutics Market, Global, Revenue ($m), 2006 - 2011 17
Table 4: Xerostomia Therapeutics Market, Global, Forecast ($m), 2011 - 2019 18
Table 5: Xerostomia Therapeutics Market, The US, Revenue ($m), 2006 - 2011 19
Table 6: Xerostomia Therapeutics Market, The US, Forecast ($m), 2011 - 2019 20
Table 7: Xerostomia Therapeutics Market, The UK, Revenue ($m), 2006 - 2011 21
Table 8: Xerostomia Therapeutics Market, The UK, Forecast ($m), 2011 - 2019 22
Table 9: Xerostomia Therapeutics Market, France, Revenue ($m), 2006 - 2011 23
Table 10: Xerostomia Therapeutics Market, France, Forecast ($m), 2011 - 2019 24
Table 11: Xerostomia Therapeutics Market, Germany, Revenue ($m), 2006 - 2011 25
Table 12: Xerostomia Therapeutics Market, Germany, Forecast ($m), 2011 - 2019 26
Table 13: Xerostomia Therapeutics Market, Italy, Revenue ($m), 2006 - 2011 27
Table 14: Xerostomia Therapeutics Market, Italy, Forecast ($m), 2011 - 2019 28
Table 15: Xerostomia Therapeutics Market, Spain, Revenue ($m), 2006 - 2011 29
Table 16: Xerostomia Therapeutics Market, Spain, Forecast ($m), 2011 - 2019 30
Table 17: Xerostomia Therapeutics Market, Japan, Revenue ($m), 2006 - 2011 31
Table 18: Xerostomia Therapeutics Market, Japan, Forecast ($m), 2011 - 2019 32
Table 19: Xerostomia Disease Therapeutics Product Profiles, Incidence of Grade 2 or Higher Xerostomia 38
Table 20: Xerostomia Therapeutics, Phase II Pipeline, 2011 41
Table 21: Xerostomia Therapeutics, Clinical Trials by Country, 2011 45
Table 22: Xerostomia Therapeutics, Clinical Trials by Phase, 2011 46
Table 23: Xerostomia Therapeutics, Clinical Trials by Status, 2011 47
Table 24: Xerostomia Therapeutics, Prominent Sponsors, 2011 49
Table 25: Xerostomia Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 50
Table 26: Parion Sciences - Sjogren's Syndrome (Associated with Xerostomia) Therapeutics Pipeline, 2011 54
Table 27: Acacia Pharma Pipeline for Xerosomia Therapeutics, 2011 54
Table 28: Marillion Pharmaceuticals, Pipeline for Xerostomia Therapeutics, 2011 55
Table 29: Xerostomia Therapeutics, Global, Deals, 2009-2011 56
List of Figures1.2 List of FiguresFigure 1: Examples of Drugs That Cause Xerostomia 7
Figure 2: Xerostomia Therapeutics Market, Global, Revenue ($m), 2006 - 2011 17
Figure 3: Xerostomia Therapeutics Market, Global, Forecast ($m), 2011 - 2019 18
Figure 4: Xerostomia Therapeutics Market, The US, Revenue ($m), 2006 - 2011 19
Figure 5: Xerostomia Therapeutics Market, The US, Forecast ($m), 2011 - 2019 20
Figure 6: Xerostomia Therapeutics Market, The UK, Revenue ($m), 2006 - 2011 21
Figure 7: Xerostomia Therapeutics Market, The UK, Forecast ($m), 2011 - 2019 22
Figure 8: Xerostomia Therapeutics Market, France, Revenue ($m), 2006 - 2011 23
Figure 9: Xerostomia Therapeutics Market, France, Forecast ($m), 2011 - 2019 24
Figure 10: Xerostomia Therapeutics Market, Germany, Revenue ($m), 2006 - 2011 25
Figure 11: Xerostomia Therapeutics Market, Germany, Forecast ($m), 2011 - 2019 26
Figure 12: Xerostomia Therapeutics Market, Italy, Revenue ($m), 2006 - 2011 27
Figure 13: Xerostomia Therapeutics Market, Italy, Forecast ($m), 2011 - 2019 28
Figure 14: Xerostomia Therapeutics Market, Spain, Revenue ($m), 2006 - 2011 29
Figure 15: Xerostomia Therapeutics Market, Spain, Forecast ($m), 2011 - 2019 30
Figure 16: Xerostomia Therapeutics Market, Japan, Revenue ($m), 2006 - 2011 31
Figure 17: Xerostomia Therapeutics Market, Japan, Forecast ($m), 2011 - 2019 32
Figure 18: Opportunity and Unmet Need in the Sjogren's Syndrome Patients Experiencing Xerostomia 34
Figure 19: Opportunity and Unmet Need in the Xerostomia Patients Derived from the Head and Neck Cancer Patients Pool 35
Figure 20: Strategic Competitor Assessment of the Major Marketed Products in Xerostomia, 2011 36
Figure 21: Xerostomia Therapeutics - Pipeline by Phase of Development, 2011 41
Figure 22: Xerostomia Therapeutics, Technology Trends Analytics Framework, 2011 42
Figure 23: Xerostomia Therapeutics, Technology Trends Analytics Framework, Description, 2011 42
Figure 24: Xerostomia Therapeutics, Pipeline by Mechanism of Action, 2011 43
Figure 25: Xerostomia Therapeutics, Clinical Trials by Country, 2011 45
Figure 26: Xerostomia Therapeutics, Clinical Trials by Phase (%), 2011 46
Figure 27: Xerostomia Therapeutics, Clinical Trials by Status, 2011 47
Figure 28: Xerostomia Therapeutics, Overall Sponsors (%), 2011 48
Figure 29: Xerostomia Therapeutics, Prominent Sponsors (%), 2011 49
Figure 30: Xerostomia Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 50
Figure 31: Xerostomia Therapeutics Market, Drivers and Barriers, 2011 51
Figure 32: Implications for Future Market Competition in the Xerostomia Market, 2011 51
Figure 33: Xerostomia Therapeutics, Clinical Pipeline by Company, 2011 53
Companies MentionedParion SciencesAcacia Pharma
Marillion Pharmaceuticals
To order this report:Therapy Industry: Xerostomia Therapeutics - Pipeline Assessment and Market Forecasts to 2019More
Market Research ReportCheck our
Industry Analysis and InsightsContact
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker